2025
Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium.
Trongtorsak A, De La Rosa Martinez J, Crawford T, Bogun F, Gu X, Purroll E, Ellenbogen K, Chicos A, Roukoz H, Zimetbaum P, Kalbfleisch S, Murgatroyd F, Steckman D, Rosenfeld L, Soejima K, Bhan A, Vedantham V, Dickfeld T, De Lurgio D, Platonov P, Zipse M, Nishiuchi S, Ortman M, Narasimhan C, Patton K, Rosenthal D, Mukerji S, Hoogendoorn J, Zeppenfeld K, Torosoff M, Judson M, Martin K, Madias C, Hermel M, Nour K, Torbey E, Sauer W, Kron J. Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium. Circulation Arrhythmia And Electrophysiology 2025, e013670. PMID: 40557494, DOI: 10.1161/circep.124.013670.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCardiac sarcoidosisVentricular ejection fractionBlack patientsEjection fractionNo significant differenceClinical outcomesPrimary outcomeWhite patientsImplantable cardioverter defibrillator therapyLeft ventricular assist device implantationSignificant differenceVentricular assist device implantationComposite end pointChronic kidney diseaseChronic obstructive pulmonary diseaseAll-cause mortalityAssist device implantationRates of lungRates of hypertensionObstructive pulmonary diseaseImplantable cardioverter defibrillatorExtracardiac involvementEye involvementHeart transplantationPart I. Dermatologic Manifestations in Patients with Kidney Disease
Singal A, Liu J, Cowper S, Ko C, Kroshinsky D, Lipner H, Robinson-Bostom L, Yosipovitch G, Lipner S. Part I. Dermatologic Manifestations in Patients with Kidney Disease. Journal Of The American Academy Of Dermatology 2025 PMID: 40543664, DOI: 10.1016/j.jaad.2025.06.035.Peer-Reviewed Original ResearchChronic kidney diseaseChronic kidney disease patientsDermatological manifestationsKidney diseaseLack of consensus guidelinesAvoidance of complicationsCKD-associated pruritusPorphyria cutanea tardaUremic frostHistopathological presentationPrompt recognitionConsensus guidelinesPigmentary changesDifferential diagnosisPerforating disordersNail changesCutanea tardaDermatological diseasesPatientsUnique dermatosisDiseaseManifestationsComplicationsPruritusDermatosesAssessing Rural Veterans' Experiences with a Tele-Nephrology Program in the Veterans Health Administration (VHA).
Mattocks K, Walker L, Kroll-Desrosiers A, Crowley S, Moore D, Bonegio R. Assessing Rural Veterans' Experiences with a Tele-Nephrology Program in the Veterans Health Administration (VHA). American Journal Of Nephrology 2025 PMID: 40527310, DOI: 10.1159/000546917.Peer-Reviewed Original ResearchVeterans Health AdministrationNephrology careSpecialty providersVeterans' perceptionsVeterans' experiencesVeterans receiving careVA Medical CenterSemi-structured interviewsMISSION ActPrimary careClinical partnershipsVeterans' healthSpecialty careVirtual careDiverse veteransChronic kidney diseaseHealth AdministrationNephrology programsCareIncrease accessVeteransMedical CenterRefractory hypertensionRural areasHigher mortality rateCorrection: Prevalence of chronic kidney disease among young people living with HIV in Sub Saharan Africa: A systematic review and meta-analysis
Nasuuna E, Nanyeenya N, Kibirige D, Izudi J, Chikwari C, Kalyesubula R, Castelnuovo B, Tomlinson L, Weiss H. Correction: Prevalence of chronic kidney disease among young people living with HIV in Sub Saharan Africa: A systematic review and meta-analysis. PLOS ONE 2025, 20: e0326624. PMID: 40526591, PMCID: PMC12173373, DOI: 10.1371/journal.pone.0326624.Peer-Reviewed Original ResearchUremic toxin receptor NR1H3 contributes to hyperlipidemia- and chronic kidney disease-accelerated vascular inflammation, which is partially suppressed by novel YBX2 anti-ROS pathway
Lu Y, Sun Y, Saaoud F, Xu K, Shao Y, Han B, Jiang X, Martinez L, Vazquez-Padron R, Mohsin S, Zhao H, Wang H, Yang X. Uremic toxin receptor NR1H3 contributes to hyperlipidemia- and chronic kidney disease-accelerated vascular inflammation, which is partially suppressed by novel YBX2 anti-ROS pathway. Redox Biology 2025, 85: 103724. PMID: 40505347, PMCID: PMC12182350, DOI: 10.1016/j.redox.2025.103724.Peer-Reviewed Original ResearchChronic kidney diseaseReactive oxygen speciesROS regulationNephrectomy-induced chronic kidney diseaseVascular inflammationRNA-binding proteinsReactive oxygen species regulationPromote vascular inflammationPromotion of inflammationCellular ROS levelsTrained immunityDisease progressionKidney diseaseMouse modelCytokine genesMouse aortaProinflammatory genesTranscription factorsRisk factorsRegulating inflammationHyperlipidemiaCardiovascular diseaseInflammationNegative feedback mechanismYBX2Fertile Ground for Mathematical Modeling: Therapeutic and Diagnostic Nanoparticle Transport in the Glomerulus
Richfield O, Cortez R, Navar L, Pober J, Zheng J, Saltzman W. Fertile Ground for Mathematical Modeling: Therapeutic and Diagnostic Nanoparticle Transport in the Glomerulus. Regenerative Engineering And Translational Medicine 2025, 1-17. DOI: 10.1007/s40883-025-00424-x.Peer-Reviewed Original ResearchChronic kidney diseaseGlomerular diseaseTreat glomerular diseasesKidney diseaseMaintenance of fluid balanceGlomerular filtration barrierTherapeutic optionsGlomerular hemodynamicsGlomerular pathologyFluid balanceGlomerular cellsGlomerular dysfunctionKidney failureRenal glomeruliGlomeruliHuman kidneyGlomerular capillariesNanoparticle transportUrine formationDiseaseFiltration barrierNP transportKidneyNP interactionsPhysiological maintenanceResolution of acute kidney injury following intensive dialysis for oxalate nephropathy.
Roth J, Buglioni A, Dahl N. Resolution of acute kidney injury following intensive dialysis for oxalate nephropathy. Clinical Nephrology 2025 PMID: 40454527, DOI: 10.5414/cn111664.Peer-Reviewed Original ResearchAcute kidney injuryOxalate nephropathyKidney injuryStage III acute kidney injuryIII acute kidney injuryResolution of acute kidney injuryUrinary excretion of oxalateIncreased urinary excretion of oxalateAbsorption of dietary oxalateDeposition of calcium oxalate crystalsIncreased absorption of dietary oxalateSerum oxalate levelsExcretion of oxalateIncreased urinary excretionChronic kidney diseaseRenal outcomesRenal recoveryEnteric hyperoxaluriaBariatric proceduresFat malabsorptionIntensive dialysisSecondary hyperoxaluriaRenal parenchymaBiliopancreatic diversionBariatric patientsModulation of the thiol redox proteome by sugarcane ash-derived silica nanoparticles: Insights into chronic kidney disease of unknown etiology
Stem A, Michel C, Harris P, Rogers K, Gibb M, Roncal-Jimenez C, Reisdorph R, Johnson R, Roede J, Fritz K, Brown J. Modulation of the thiol redox proteome by sugarcane ash-derived silica nanoparticles: Insights into chronic kidney disease of unknown etiology. Free Radical Biology And Medicine 2025, 233: s44. DOI: 10.1016/j.freeradbiomed.2025.05.158.Peer-Reviewed Original ResearchDisease of unknown etiologyChronic kidney diseaseUnknown etiologyChronic kidney disease of unknown etiologyExecutive summary for the China Kidney Disease Network (CK-NET) 2017–2018 Annual Data Report
Yang C, Gao B, Wang F, Chu H, Wang J, Sun X, Zhang P, Xu H, Mao H, Xing C, Chen M, Zuo L, Wang Y, Yu F, Zhang H, Wang H, Chen J, Zhang L, Zhao M, Group C. Executive summary for the China Kidney Disease Network (CK-NET) 2017–2018 Annual Data Report. Kidney International 2025, 107: 980-984. PMID: 40404261, DOI: 10.1016/j.kint.2024.12.017.Peer-Reviewed Original ResearchImpact of improved diagnosis and treatment on holistic chronic kidney disease burden
Tangri N, Priest S, Zara A, Long B, Chen J, Rao N, Froguel C, Robson B, Guldemond N, Eckelman M, Moura A, Audehm R, Adshead F, Zhao M, Wanner C, Chadban S. Impact of improved diagnosis and treatment on holistic chronic kidney disease burden. Kidney International Reports 2025 DOI: 10.1016/j.ekir.2025.05.039.Peer-Reviewed Original ResearchGuideline-directed medical therapyChronic kidney diseaseKidney replacement therapyGDMT adherenceImpact of chronic kidney diseaseTreatment of chronic kidney diseaseBurden of chronic kidney diseaseDelay CKD progressionChronic kidney disease burdenHealthcare systemMedical therapyReplacement therapyAdherence scenariosCKD progressionCardiovascular eventsUndertreated diseaseGuideline changesMultiple therapiesAvailability of effective interventionsLipid loweringKidney protectionKidney diseaseCKD modelGlucose loweringLifestyle interventionCandidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1
Rosende A, Romero C, DiPette D, Brettler J, Van der Stuyft P, Satheesh G, Perel P, Chapman N, Moran A, Schutte A, Sharman J, Irazola V, Huffman M, Campbell N, Salam A, Lanas F, Coca A, Garcia-Zamora S, Ferreiro A, Lopez-Jaramillo P, Rico-Fontalvo J, Ridley E, Picone D, Flood D, Piñeiro D, Ojeda C, Rodriguez G, Wellmann I, Orias M, Rivera M, Reyes M, Onuma O, Ramroop S, Khan T, Gonzalez Y, Barroso W, Plavnik F, Zuniga E, Grassani A, Tajer C, Zaidel E, Marin M, Cyr-Philbert S, Amorin I, Aguilera M, Bortolotto L, Avezum A, Ribeiro A, Tobe S, Aumala T, Angell S, Lavados P, Martins S, Echeverri A, Jaffe M, Prabhakaran D, Parati G, Zhang X, Rodgers A, Yusuf S, Whelton P, Ordunez P. Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1. Global Heart 2025, 20: 45. PMID: 40454106, PMCID: PMC12124280, DOI: 10.5334/gh.1428.Peer-Reviewed Original ResearchConceptsClinical pathwayNon-physician health workersTeam-based careImprove care deliveryReduce care fragmentationPrimary care settingPrimary health settingsCare of hypertensionGlobal Hearts InitiativeCommunity-based screeningEvidence-based interventionsManagement of risk factorsHigher CVD riskLower blood pressure thresholdHigh CVD risk patientsCardiovascular diseaseChronic kidney diseasePhase 1Blood pressure thresholdsHealth equityCare fragmentationHearts InitiativePrimary careCare deliveryHealth settingsLong-Term Exposure to Uranium and Arsenic in Community Drinking Water and CKD Risk Among California Women
Medgyesi D, Mohan S, Bangia K, Spielfogel E, Spaur M, Basu A, Fisher J, Madrigal J, Domingo-Relloso A, Jones R, Ward M, Lacey J, Sanchez T, Investigators C. Long-Term Exposure to Uranium and Arsenic in Community Drinking Water and CKD Risk Among California Women. American Journal Of Kidney Diseases 2025 PMID: 40381930, DOI: 10.1053/j.ajkd.2025.04.008.Peer-Reviewed Original ResearchChronic kidney disease riskCommunity water suppliesCKD riskRegulatory limitsParticipant's residential addressNeighborhood socioeconomic statusCommunity waterCalifornia Teachers StudyAssociated with CKD riskChronic kidney diseaseCardiovascular diseaseAssociated with riskDrinking waterAbstractText Label="PLAIN-LANGUAGE SUMMARYBody mass indexIncreased CKD riskYoung individualsHigh uranium concentrationsCommunity drinking waterWater supplyResidential addressesArsenic concentrationsDamage kidney functionSocioeconomic statusAssociated with chronic kidney diseaseDeclining Serum Albumin with Stable BMI: A Mortality Indicator in Pre- Dialysis CKD
Sarav M, Shrestha P, Naseer A, Thomas F, Sumida K, Kalantar-Zadeh K, Kovesdy C. Declining Serum Albumin with Stable BMI: A Mortality Indicator in Pre- Dialysis CKD. Journal Of Renal Nutrition 2025 PMID: 40339729, DOI: 10.1053/j.jrn.2025.04.005.Peer-Reviewed Original ResearchStable body mass indexAdvanced chronic kidney diseaseBody mass indexChronic kidney diseaseCohort of US veteransPre-dialysis chronic kidney diseasePredialysis chronic kidney diseaseClinically relevant declineChronic kidney disease managementComprehensive nutritional assessmentSerum albumin levelAfrican American participantsProportion of patientsDialysis chronic kidney diseaseCox proportional hazards modelsKidney replacement therapySerum albumin measurementProportional hazards modelMortality indicatorsPredialysis periodUS veteransReplacement therapyAlbumin levelsNutritional markersNationwide cohortImpact of the Kidney Score Platform on Communication About and Patients’ Engagement With Chronic Kidney Disease Health: Pre–Post Intervention Study
Tuot D, Crowley S, Katz L, Leung J, Alcantara-Cadillo D, Ruser C, Talbot-Montgomery E, Vassalotti J. Impact of the Kidney Score Platform on Communication About and Patients’ Engagement With Chronic Kidney Disease Health: Pre–Post Intervention Study. JMIR Formative Research 2025, 9: e56855. PMID: 40300154, PMCID: PMC12054969, DOI: 10.2196/56855.Peer-Reviewed Original ResearchConceptsPre-post intervention studyPatient Activation MeasureKidney healthPractice toolkitIntervention studiesIncrease patient activationDiabetes statusPrimary care cliniciansPrimary care settingPercentage of veteransChronic kidney diseaseUS adult populationClinical practice guidelinesChronic kidney disease managementChronic kidney disease education programClinician engagementPatient engagementCare cliniciansCare settingsPaired t-testPatient knowledgeTailored educationKnowledge scoresPatient activationPatient interactionsAortic valve calcium as a novel risk marker for kidney function deterioration: The MESA study
Abdollahi A, Sani M, Shabani M, Matuck B, Blaha M, Wu C, Ambale-Venkatesh B, Budoff M, Strom J, Rotter J, Post W, Blumenthal R, Bluemke D, Ghahramani N, Lima J, Whelton S. Aortic valve calcium as a novel risk marker for kidney function deterioration: The MESA study. European Journal Of Internal Medicine 2025, 136: 49-55. PMID: 40263084, DOI: 10.1016/j.ejim.2025.03.037.Peer-Reviewed Original ResearchConceptsMulti-Ethnic Study of AtherosclerosisRisk of incident chronic kidney diseaseIncident chronic kidney diseaseAortic valve calciumInternational Classification of DiseasesChronic kidney diseaseCardiac CT scansAdjusted Cox proportional hazards regression modelsMultivariable adjusted Cox proportional hazards regression modelsParticipants free of chronic kidney diseaseCardiovascular diseaseMulti-Ethnic Study of Atherosclerosis studyValve calciumCT scanCVD risk factorsHistory of cardiovascular diseaseCategorized as 0Higher risk of incident CKDFree of chronic kidney diseaseAssociated with increased risk of mortalityMulti-Ethnic StudyAtherosclerotic CVD risk factorsMulti-ethnic cohortAPOE-e4 genotypeClassification of DiseasesOutcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial Presented at the Southern Association for Vascular Surgery Forty-ninth Annual Meeting, Frenchman's Reef in St. Thomas, USVI, January 22-25, 2025.
Malas M, Hamouda M, Farber A, Menard M, Conte M, Rosenfield K, Strong M, Doros G, Powell R, Mena-Hurtado C, Gasper W, Schermerhorn M, Allievi S, Smolderen K, Dake M, Rymer J, Tuttle K. Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial Presented at the Southern Association for Vascular Surgery Forty-ninth Annual Meeting, Frenchman's Reef in St. Thomas, USVI, January 22-25, 2025. European Journal Of Vascular And Endovascular Surgery 2025, 69: e262-e263. DOI: 10.1016/j.ejvs.2025.02.053.Peer-Reviewed Original ResearchOral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
Marx N, Deanfield J, Mann J, Arechavaleta R, Bain S, Bajaj H, Tanggaard K, Birkenfeld A, Buse J, Davicevic-Elez Z, Desouza C, Emerson S, Engelmann M, Hovingh G, Inzucchi S, Jhund P, Mulvagh S, Pop-Busui R, Poulter N, Rasmussen S, Tu S, McGuire D, Group O. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation 2025, 151: 1639-1650. PMID: 40156843, PMCID: PMC12144549, DOI: 10.1161/circulationaha.125.074545.Peer-Reviewed Original ResearchConceptsOral semaglutideType 2 diabetesAdverse cardiovascular eventsCardiovascular eventsCardiovascular outcomesAdverse cardiovascular events outcomeEffects of oral semaglutidePrimary outcomeMajor adverse cardiovascular events outcomeAdverse event profilePrimary outcome eventNonfatal myocardial infarctionChronic kidney diseaseAtherosclerotic cardiovascular diseaseCardiovascular event outcomesSGLT2i treatmentSGLT2i useReceptor agonistsAdverse eventsPrespecified analysesFollow-upCardiovascular deathRandomized trialsSemaglutideNonfatal strokeThe Use of Intravascular Ultrasound During Deep Venous Interventions in a Tertiary Care Center
Ali S, Rodriguez P, Abualanain E, Li Y, Khalil M, Aboloyoun H, Lozada J, Aboian E, Attaran R, Chaar C. The Use of Intravascular Ultrasound During Deep Venous Interventions in a Tertiary Care Center. Vascular And Endovascular Surgery 2025, 59: 505-512. PMID: 40096827, DOI: 10.1177/15385744251326989.Peer-Reviewed Original ResearchConceptsDeep venous interventionsPrimary patency rateVenous interventionsLoss of patencyPatency ratesAssociated with loss of patencyAssociated with fewer complicationsIVUS useMethodsThis retrospective studyTertiary care centerLower extremity interventionsChronic kidney diseaseMultiplanar venographyAssociated with lossConsecutive patientsRates of COPDPrimary patencyVenous stentingTechnical successFewer complicationsSymptomatic improvementVenous stenosisAnticoagulant useRetrospective studyHypercoagulable stateAdding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury
Baker M, Cantley L. Adding insult to injury: the spectrum of tubulointerstitial responses in acute kidney injury. Journal Of Clinical Investigation 2025, 135: e188358. PMID: 40091836, PMCID: PMC11910233, DOI: 10.1172/jci188358.Peer-Reviewed Original ResearchConceptsAcute kidney injuryTubular epithelial cellsKidney injuryTubular cellsCases of acute kidney injuryImmune-mediated processPersistence of inflammationBiphasic immune responseChronic kidney diseaseCell deathTubular cell injuryLymphocyte subsetsTubular repairCell cycle arrestOutflow obstructionTEC differentiationPreclinical findingsLymphocytic infiltrationProinflammatory macrophagesKidney diseaseModulate inflammationImmune responseActivated macrophagesMetabolic reprogrammingTubular castsBiomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease
Li M, Jiang L, Liu Z, You R, Li Y, Xiang C, Yang L, Zhang H, Zhou X. Biomarkers in Autosomal Dominant Tubulointerstitial Kidney Disease. Integrative Medicine In Nephrology And Andrology 2025, 12 DOI: 10.1097/imna-d-24-00050.Peer-Reviewed Original ResearchAutosomal dominant tubulointerstitial kidney diseaseChronic kidney diseaseTubulointerstitial kidney diseaseKidney diseaseProgressive chronic kidney diseaseDelay kidney failureVariable clinical featuresUric acid levelsControl blood pressureRenal interstitial fibrosisImprove patient outcomesPotential therapeutic targetClinical featuresClinical manifestationsTreatment optionsInterstitial fibrosisInsidious onsetClinical indicationsDisease progressionTubular proteinuriaEarly diagnosisBlood pressurePathological featuresAdvanced stageKidney failure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply